^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR T790M + EGFR C797S |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | BI-732 (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4476 / 1 - BI-732, a novel fourth-generation EGFR-TKI, demonstrates promising activities against the C797S-mediated EGFR-TKI resistance
Published date:
03/15/2023
Excerpt:
We further confirmed the superior antiproliferative efficacy of BI-732 in PC9-DC (IC50, 24.9 nM), YU-1182 (IC50, 73 nM) and YU-1097 cells (IC50, 2.9 nM)….Our findings suggest that BI-732 can be effective against EGFR mutant NSCLC, especially EGFRDel19/T790M/C797S and EGFRDel19/C797S, that have progressed with previous EGFR inhibitors.
